Small molecule inhibitors with specificity for MerTK/FLT3, such as MRX2843 and UNC1666, have shown a substantial impact on cell growth in acute myeloid leukemia (AML); acute lymphoblastic leukemia (ALL); and melanoma in various experimental settings, including cell lines, murine models, and primary patient tumor samples [116,117]. The gene discussed is MERTK; the disease is acute lymphoblastic leukemia.